EU firms facing new requirements for orphan drug designation
This article was originally published in Scrip
Companies developing products for rare diseases in the EU could be facing changes to the requirements for gaining orphan drug designation, after the European Commission announced that it planned to review the criteria for showing that a new product has a "significant benefit" over existing treatments.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.